On 2 September 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637.HK) announced that HX9428 had filed a Phase IIa IND for diabetic macular edema with the CDE of NMPA on 31 August 2026; the Phase I dose-escalation study in neovascular age-related macular degeneration was fully completed, with 13 patients finishing 24 weeks of dosing without additional intravitreal injections and average visual acuity improvement exceeding 5 letters. The drug has received Fast Track Designation from the US FDA.
On 2 September 2026, HONGHUA GROUP (00196.HK) announced that its subsidiary Sichuan Honghua has signed drilling rig sales agreements with a Middle East customer totalling RMB 600 million, with the rigs to be equipped with self-developed intelligent systems.
On 2 September 2026, PEGBIO CO-B (02565.HK) announced a material transfer agreement with Korean biotech SN BioScience to apply its SNA long-acting delivery platform to three metabolic disease peptide candidates including APGP6.
NewTimeSpace News: On 1 September 2026, LAEKNA-B (02105.HK) announced that the first subject has been enrolled in the Phase I clinical study of LAE118, a novel PI3Kα pan-mutation selective inhibitor, for advanced solid tumours in China; the drug has received IND approval from the US FDA and CDE, and in June 2026 the Group entered into an exclusive licence agreement with Vasque Bio providing for payments of up to USD 527 million.
NewTimeSpace News: On August 31, 2026, Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary CTTQ has entered into an exclusive license and supply agreement with Cipla for TQB2102, a HER2 bispecific ADC, granting Cipla an exclusive license to develop and commercialize the drug in India, South Africa and five other emerging markets, with milestone payments of up to USD 123 million plus double-digit royalties. This is the second regional licensing collaboration for TQB2102; the two collaborations have together brought approximately USD 30 million in upfront and milestone payments.
This week's going-global focus centers on two threads: dense overseas clinical approvals for innovative drugs — two new drugs from CSPC PHARMA won US FDA recognition, and bispecific-antibody pipelines from BAO PHARMA and ANTENGENE received US and Australian regulatory approvals respectively — and accelerated Hong Kong financing, with SHEIN and Mech-Mind launching global offerings, LONGSYS passing its listing hearing, and LEADERDRIVE and Nazhen Technology advancing H-share listings. On the resources side, Mongolia's iron ore project has entered the construction phase and GUSHENGTANG is acquiring 100% of three Malaysian TCM institutions, as Chinese companies' global expansion evolves toward multidimensional coordination of technology, capital and channels.
NewTimeSpace News: On 28 August 2026, WEI YUAN HLDG (01343.HK) announced that WGC, its indirect wholly-owned subsidiary, has accepted the JTC consent letter to proceed with the redevelopment of the property in Singapore, raising the aggregate plot ratio from 0.85 and 0.90 to 1.40 on a combined basis, with completion required within two years from the date of the consent letter; the redevelopment may constitute a discloseable transaction under Chapter 14 of the Listing Rules.
NewTimeSpace News: Wai Chun Bio-Technology announced on August 25 that the Company has entered into a memorandum of understanding for strategic cooperation with multiple parties for the integrated AI digital‑infrastructure ecosystem project in Pahang Aviation City, Malaysia. The master‑planned site covers over 1,200 acres, with a planned IT load of 300 MW for the first‑phase development.
NewTimeSpace News: Jiaxin International Resources announced on August 24 that its subsidiary ZV entered into the Bakuta Mining Construction Contract with CCECC Kazakhstan Branch via public tender for the expansion project of No.1 tailings pond of the Bakuta Tungsten Mine. The initial contract price stands at approximately RMB 257 million (tax‑included), capped at roughly RMB 306 million.
NewTimeSpace News: On 24 August 2026, YANCOAL AUS (03668.HK) announced an increase in the annual cap under the Glencore framework coal sales agreement for the year ending 31 December 2026 from USD 350 million to USD 750 million, driven by higher spot purchase demand amid Middle East conflict turmoil and increased HVO spot sales, with H1 transaction volume of approximately USD 215 million.
NewTimeSpace News: On 23 August 2026, SUNSHINE OIL (02012.HK) announced that its wholly-owned subsidiary Sangxiang Petrochemical, holding a 40% stake, jointly established Deneng Zhisuan Artificial Intelligence Co., Ltd. in Beidaihe, Qinhuangdao with five JV partners to build a 6,000P computing power centre, supported by the Beidaihe government with a subsequent government-controlled equity stake.
This week's cross-border activities highlight biopharma and resources. Henlius partnered with Sandoz for up to 10 biosimilars globally, with combined milestone and upfront payments up to $314 million. Gaoshi Medical's corneal confocal microscope secured exclusive global distribution via HEIDELBERG. Sinopec Oilfield Service acquired a stake in a Mexican oilfield, while MMG's Las Bambas mine resumed operations after a suspension due to a fatal accident. On the financing front, Beijing Junzheng, ASR Microelectronics, Xingyu Auto, and Hunan Yuneng are advancing H-share listings to accelerate access to international capital.
NewTimeSpace News: On 19 August 2026, 5100 XIZANG (01115.HK) announced that its wholly-owned subsidiary entered into a distribution contract with Malaysia's Landmark Holding Sdn. Bhd., granting exclusive distribution rights in Malaysia and non-exclusive rights in Southeast Asian and Middle East export markets, with an initial three-year term renewable upon meeting performance targets, accelerating its overseas expansion.
NewTimeSpace News: On 17 August 2026, CHINAGOLDINTL (02099.HK) announced the engagement of SRK Consulting to conduct an independent feasibility study stage assessment of the proposed underground development project at the Changshanhao Gold Mine and prepare an NI 43-101 technical report, with block caving proposed for the transition from open-pit to underground mining and pre-development works already commenced; SRK's work will proceed in two stages of gap analysis and independent feasibility study.
NewTimeSpace News: On 17 August 2026, SHOUGANG CENT (00103.HK) announced the signing of a cooperation letter of intent with Beauty Realm Capital to jointly establish a joint venture in the tyre reinforcement materials sector and expand the global industrial rayon market; Beauty Realm Capital is the controlling shareholder of Cordenka, a globally leading industrial rayon producer, and a formal agreement is subject to further negotiation.
NewTimeSpace News: On 17 August 2026, SINOPEC SSC (01033.HK) announced that its wholly-owned subsidiary will acquire a 50% interest in Mexico DS and a 0.01% interest in the EBANO project for USD 4 million, indirectly holding a 55% interest in the EBANO project after completion, with follow-on investment of up to USD 212 million; the EBANO oilfield holds geological reserves of 4.92 billion barrels, and the acquisition does not constitute a connected transaction or major asset restructuring.
